TVTX Travere Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Travere Therapeutics, Inc. (TVTX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 19, 2026, a 10-Q quarterly report filed on October 30, 2025, an 8-K current report filed on April 14, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Travere Therapeutics, Inc. (TVTX) (SEC CIK 1438533), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Developing, manufacturing outsourced, and commercializing pharmaceutical products, including marketed drug FILSPARI and pipeline candidates
- • New emphasis on pegtibatinase Phase 3 HARMONY Study resumed in 2026 after voluntary enrollment pause in Sept 2024 due to manufacturing scale-up issues
Risk Factors
- • Cybersecurity risk management overseen by Nominating / Corporate Governance Committee reporting to board
- • Cybersecurity incident team with cross-functional expertise including IT, legal, compliance, and privacy functions
Management Discussion & Analysis
- • Revenue specifics and YoY changes not disclosed in provided MD&A section
- • Profitability or margin figures absent; no actual % margins reported
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New commercialization risk: FDA full approval of FILSPARI in Sept 2024 replacing prior accelerated approval in Feb 2023 requires expanded U.S. sales force training and market adoption efforts
- • Most material update: Expanded risks on third-party commercialization outside U.S. due to CSL Vifor acquisition by CSL Limited and possible reduced marketing support
Annual Reports Archive10-K
AI-powered analysis of Travere Therapeutics, Inc. (TVTX) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Travere Therapeutics, Inc. (TVTX) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $212.0M | $145.2M | $233.2M | $490.7M |
| Operating Income | -$266.6M | -$388.1M | -$323.8M | -$62.8M |
| Net Income | -$278.5M | -$111.4M | -$321.5M | -$25.5M |
| Op. Margin | -125.7% | -267.2% | -138.9% | -12.8% |
| Net Margin | -131.3% | -76.7% | -137.9% | -5.2% |
| Balance Sheet | ||||
| Total Assets | $672.6M | $788.9M | $594.1M | $605.2M |
| Equity | $42.9M | $200.8M | $59.1M | $114.8M |
| ROE | -649.9% | -55.5% | -544.3% | -22.2% |
Source: XBRL financial data from Travere Therapeutics, Inc. (TVTX) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 14, 2026 | — | — | — |
10-K | Feb 19, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 19, 2026 | — | — | |
8-K | Jan 13, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Oct 30, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | May 1, 2025 | Mar 31, 2025 | — | |
10-K | Feb 21, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 31, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | — | |
10-Q | May 6, 2024 | Mar 31, 2024 | — | |
10-K | Feb 20, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 7, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Feb 23, 2023 | Dec 31, 2022 | — | |
10-Q | Oct 27, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Feb 24, 2022 | Dec 31, 2021 | — | |
10-Q | Oct 29, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 29, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Mar 1, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest TVTX SEC filings in 2026?
Travere Therapeutics, Inc. (TVTX) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 30, 2025, an 8-K current report on April 14, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did TVTX file its most recent 10-K annual report?
Travere Therapeutics, Inc. (TVTX) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view TVTX 10-Q quarterly reports?
Travere Therapeutics, Inc. (TVTX)'s most recent 10-Q quarterly report was filed on October 30, 2025. SignalX displays every TVTX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has TVTX filed recently?
Travere Therapeutics, Inc. (TVTX)'s most recent 8-K was filed on April 14, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find TVTX insider trading activity (Form 4)?
SignalX aggregates every TVTX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does TVTX file with the SEC?
Travere Therapeutics, Inc. (TVTX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TVTX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Travere Therapeutics, Inc. (TVTX).
What is TVTX's SEC CIK number?
Travere Therapeutics, Inc. (TVTX)'s SEC CIK (Central Index Key) number is 1438533. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1438533 to look up all TVTX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find TVTX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Travere Therapeutics, Inc. (TVTX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Travere Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 51+ filings.